Prima BioMed Ltd. (PBMD) Upgraded at Zacks Investment Research
According to Zacks, “Prima Biomed Ltd is a biotechnology company focused on developing oncology therapies in the field of immunotherapy. The Company’s key product candidates in development include CVac, an autologous dendritic cell vaccine for ovarian cancer, monoclonal antibodies for multiple tumor types, and an oral formulation for the Human Papilloma Virus. Prima Biomed Ltd is based in Sydney, Australia. “
PBMD has been the subject of several other research reports. Maxim Group restated a buy rating on shares of Prima BioMed in a research note on Wednesday, June 8th. Roth Capital restated a buy rating and set a $6.00 price target on shares of Prima BioMed in a research note on Friday, August 26th. HC Wainwright restated a buy rating on shares of Prima BioMed in a research note on Wednesday, June 22nd. Finally, FBR & Co restated a buy rating on shares of Prima BioMed in a research note on Wednesday, June 22nd. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $4.20.
Prima BioMed (NASDAQ:PBMD) opened at 0.885 on Thursday. Prima BioMed has a 12 month low of $0.72 and a 12 month high of $1.54. The firm’s market capitalization is $60.82 million. The firm’s 50-day moving average is $0.87 and its 200 day moving average is $0.95.
About Prima BioMed
Prima BioMed Limited is an Australia-based biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. The Company focuses on cancer immunotherapy research. The Company’s main pipeline of products is based on the LAG-3 immune control mechanism, which plays a role in the regulation of the T cell immune response.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prima BioMed Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prima BioMed Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.